All In Biotech

Free tool

FAERS Monitor: Absorica Ld

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 211913 or its brand name (Absorica Ld, Isotretinoin). Reports on generic versions are filed under their own applications.

Reports

16,326

Serious

8,845

54% of reports

Hospitalization

1,411

Death reported

439

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • depression1,058
  • pregnancy1,040
  • exposure during pregnancy775
  • abortion induced728
  • adverse drug reaction670
  • product dose omission issue626
  • headache578
  • dry skin577
  • arthralgia563
  • suicidal ideation535
  • drug ineffective521
  • mood altered467
  • anxiety415
  • off label use353
  • maternal exposure during pregnancy327

Reports by year received

View as table
YearReports
2004124
2005209
2006355
2007491
2008766
2009503
2010492
2011276
2012383
2013260
2014158
2015197
2016229
2017245
2018389
2019394
2020691
20211,033
20221,547
20231,709
20242,199
20252,321
20261,355

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,037,833 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
abortion inducedSignal728107.9100.271,057
pregnancySignal1,04070.566.467,586
mood alteredSignal46722.420.59,387
exposure during pregnancySignal77516.315.210,974
adverse drug reactionSignal6709.79.05,186
suicidal ideationSignal5357.67.03,038
depressionSignal1,0586.05.74,445
dry skinSignal5775.65.22,174
maternal exposure during pregnancySignal3274.74.3962
product dose omission issueSignal6262.72.5702
anxiety4151.91.7172
arthralgia5631.71.6182
headache5781.21.117
off label use3530.50.5163
drug ineffective5210.50.5262

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.